A citation-based method for searching scientific literature

Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko, Mohamedtaki A Tejani, Anghel A Udrea, Mustapha Tehfe, Ferdinando De Vita, Cheryl Turkington, Rui Tang, Agnes Ang, Yilong Zhang, Tien Hoang, Roger Sidhu, David Cunningham. Lancet Oncol 2017
Times Cited: 180



Eric Van Cutsem, Boguslawa Karaszewska, Yoon-Koo Kang, Hyun Cheol Chung, Veena Shankaran, Salvatore Siena, Ning F Go, Hui Yang, Marco Schupp, David Cunningham. Clin Cancer Res 2019
Times Cited: 38




List of shared articles



Times cited

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
Yiting Dong, Jiachen Xu, Boyang Sun, Jie Wang, Zhijie Wang. Mol Diagn Ther 2022
1

Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches.
Sangjoon Choi, Sujin Park, Hyunjin Kim, So Young Kang, Soomin Ahn, Kyoung-Mee Kim. Biomedicines 2022
1

Targeting MET amplification in Gastro-oesophageal (GO) malignancies and overcoming MET inhibitor resistance: challenges and opportunities.
Emily Harrold, Lynda Corrigan, Simon Barry, Maeve Lowery. Expert Rev Gastroenterol Hepatol 2022
0

Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.
Daniel V T Catenacci, Stephanie Moya, Samantha Lomnicki, Leah M Chase, Bryan F Peterson, Natalie Reizine, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart,[...]. Cancer Discov 2021
21

Narrative review: mesenchymal-epithelial transition inhibitors-meeting their target.
Danish Safi, Taher Abu Hejleh, Muhammad Furqan. Transl Lung Cancer Res 2021
1

Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Yoshiaki Nakamura, Akihito Kawazoe, Florian Lordick, Yelena Y Janjigian, Kohei Shitara. Nat Rev Clin Oncol 2021
26

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program.
Thomas Aparicio, Nathalie Cozic, Christelle de la Fouchardière, Emeline Meriaux, Jérome Plaza, Laurent Mineur, Rosine Guimbaud, Emmanuelle Samalin, Florence Mary, Thierry Lecomte,[...]. Target Oncol 2021
7

Targeting the Microenvironment in Esophageal Cancer.
Lei Wang, Huiqiong Han, Zehua Wang, Litong Shi, Mei Yang, Yanru Qin. Front Cell Dev Biol 2021
3

MET inhibitors in cancer: pitfalls and challenges.
Helena Oliveres, Estela Pineda, Joan Maurel. Expert Opin Investig Drugs 2020
9

Comprehensive review of targeted therapy for colorectal cancer.
Yuan-Hong Xie, Ying-Xuan Chen, Jing-Yuan Fang. Signal Transduct Target Ther 2020
295

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress.
Valentina Gambardella, Tania Fleitas, Noelia Tarazona, Federica Papaccio, Marisol Huerta, Susana Roselló, Francisco Gimeno-Valiente, Desamparados Roda, Andrés Cervantes. J Clin Med 2020
9

Advances in targeted therapy for esophageal cancer.
Yan-Ming Yang, Pan Hong, Wen Wen Xu, Qing-Yu He, Bin Li. Signal Transduct Target Ther 2020
70

MET Inhibitors for the Treatment of Gastric Cancer: What's Their Potential?
Haidar El Darsa, Rola El Sayed, Omar Abdel-Rahman. J Exp Pharmacol 2020
7